Devonian is a clinical-stage biopharmaceutical company that develops Thykamine, a proprietary botanical drug candidate extracted from spinach thylakoid membranes, to treat inflammatory and fibrotic diseases. Thykamine acts as an anti-inflammatory, antioxidant, and immunomodulatory agent across multiple therapeutic indications. Devonian's lead development programs include topical formulations for pediatric atopic dermatitis and the prevention of radiodermatitis in oncology patients. Devonian also maintains earlier-stage programs targeting adult atopic dermatitis, ulcerative colitis, and liver fibrosis. Devonian extracts and stabilizes Thykamine at its internal facility in Montmagny, Quebec, and relies on third-party contract manufacturers to produce finished drug formulations, such as creams, enemas, and capsules. Devonian's business model centers on advancing Thykamine through clinical trials to secure out-licensing agreements with established pharmaceutical companies in exchange for upfront payments, milestone payments, and royalties on product sales. Devonian also owns Altius Healthcare, a legacy generic pharmaceutical distribution business that Devonian is evaluating for divestiture, wind-down, or repurposing.